US/UK/Canada

Share

Contacts

  • Catharina Johansson

    CFO, IR & Communications


    Medicon Village 223 81 Lund Sweden
    +46 (0)46-275 62 21
    http://www.abliva.com
  • Abliva
    +46 (0)46 275 62 20
    • Pick a time period -
    Tags ( Active)

    BioStock: From mutation to solution - Abliva gains ground

    Abliva continues to solidify its position as a leader in developing treatments for mitochondrial disease. During Q3 2024, the biotech company reached a milestone with the positive interim analysis of its FALCON trial, evaluating the drug candidate KL1333 as a potential treatment for primary mitochondrial disease.Read the article about Abliva at biostock.se:https://www.biostock.se/en/2024/12/from-mutation-to-solution-abliva-gains-ground/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    Abliva will present at the BioStock Life Science Summit, November 21

    The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CMO Magnus Hansson will present Abliva to industry leaders, specialist investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: 21 November Time: 15:10 Location: Auditorium at Medicon Village, Lund Read

    BioStock: Abliva leads the fight against mitochondrial disease

    This week, mitochondrial disease is in focus during Mitochondrial Disease Week, highlighting a condition that, despite its often severe impact, remains relatively unknown. While research has progressed, there are still no approved treatments. Swedish biotech Abliva is at the forefront of changing this, with its phase II study of drug candidate KL1333 recently reaching a significant milestone.Read the article about Abliva at biostock.se:https://www.biostock.se/en/2024/09/abliva-leads-the-fight-against-mitochondrial-diseaseThis is a press release from BioStock - Connecting Innovation &

    BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease

    Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva's development moving forward.Watch the interview with Abliva ’s CEO Ellen Donnelly at biostock.se: Abliva's CEO: We are the leading programme in mitochondrial disease - BioStock  This is a

    Abliva’s CEO to BioStock: “One step closer to a marketed medicine”

    Abliva has reported positive interim analysis results for the potentially registrational FALCON study, assessing KL1333 in patients with primary mitochondrial disease. While validating the study design and confirming KL1333’s strong safety profile, it also triggers a convertible loan conversion, providing Abliva with proceeds of 42 million SEK before transaction costs.– The interim analysis is an important de-risking event for the program, says Ellen K. Donelly, CEO of Abliva.Read the full interview with Ellen K. Donelly at biostock.se: https://www.biostock.se/en/2024/07/ablivas-ceo-

    Ablivas CEO to BioStock: “We remain on track for the interim analysis early in Q3”

    During the first quarter of 2024, Abliva focused on progressing the FALCON clinical trial towards interim analysis, securing necessary financing, and increasing the company’s visibility within the mitochondrial disease community. With funding secured, the team has all the chess pieces in place for a mid-year readout.– In their analysis, the DMC will review the safety profile of KL1333 and the potential of the study to achieve statistical significance after the full 48 weeks of dosing, says Abliva’s CEO Ellen Donnelly.Read the full interview with Ellen Donnelly at biostock.se: https://

    BioStock: Abliva’s mission to become mitochondrial medicine powerhouse

    Abliva’s CMO Magnus Hansson attended the 8[th] annual meeting of Mitochondrial Medicine – Therapeutic Development in March. The conference brings together leaders in translational mitochondrial medicine to discuss recent advances in the area of mitochondrial research and clinical development. BioStock spoke with Hansson to better understand how scientific meetings like this one fit into the company’s overall missionRead the article at biostock.se: Abliva’s mission to become mitochondrial medicine powerhouse - BioStock This is a press

    BioStock: Abliva’s CEO comments on the proposed capital raise

    Abliva’s 2023 Year-End report focuses on the successful enrolment in December for Wave 1 of the phase II 'FALCON' study with lead candidate KL1333. Other key milestones include initiating dosing and receiving Fast Track Designation for the programme. BioStock contacted Abliva’s CEO Ellen Donnelly to learn more about the most impactful milestones achieved during the quarter and the recently announced rights issue that aims to support ongoing activities and provide additional runway.Read the interview with Ellen Donnelly at biostock.se: Abliva’s CEO comments on the proposed capital raise -

    BioStock: Abliva reaches enrollment goal

    For biotech Abliva, the main focus for 2023 has been the FALCON study, a potentially registrational, global, phase II study with lead candidate KL1333. In June, Abliva began dosing patients, and yesterday the company announced that the goal of enrolling 40 patients for Wave 1 has been met. BioStock spoke to Dag Nesse, Vice President of Clinical Operations, to learn more.Read the article at biostock.se: https://www.biostock.se/en/2023/12/abliva-reaches-enrollment-goal/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    BioStock: Abliva’s CEO: ”Orphan drug designation is great validation”

    Biotech Abliva enters the holiday period on a high note with the announcement that NV354 has received orphan designation from the European Commission. The candidate is being developed for treatment of mitochondrial disease with neurologic complications,  and the designation is expected to facilitate clinical development. BioStock reached out to Abliva’s CEO Ellen K. Donnelly for a comment.Read the article at biostock.se: https://www.biostock.se/en/2023/12/ablivas-ceo-orphan-drug-designation-is-great-validation/ This is a press release from BioStock - Connecting Innovation & Capital.

    BioStock: Abliva signs global license deal for NeuroSTAT

    On Tuesday evening, Abliva announced a licensing and collaboration deal with US-based Owl Therapeutics for the development of NeuroSTAT for Traumatic Brain Injury. The deal includes potential milestone payments of 43,65 MUSD. BioStock reached out to Abliva’s CEO Ellen K. Donnelly for a comment.Read the article at biostock.se: https://www.biostock.se/en/2023/11/abliva-signs-global-license-deal-for-neurostat/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    BioStock: Abliva’s VP of Clinical Operations on the screening achievement

    Swedish biotech company Abliva has successfully met the target number of patients for screening in the first wave of the global phase II FALCON study, demonstrating their commitment to maintaining the project’s timeline. BioStock spoke with VP Clinical Operations, Dag Nesse, about this achievement in the study.Read the article at biostock.se: https://www.biostock.se/en/2023/10/ablivas-vp-of-clinical-operations-on-the-screening-achievement/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    BioStock:Abliva increases awareness of mitochondrial diseases

    As the world observes Mitochondrial Disease Week, the spotlight is on the debilitating symptom of fatigue that plagues people with mitochondrial disease. Lund-based biotech company Abliva is at the forefront of this battle with its drug candidate KL1333, currently in a global phase II study. BioStock contacted Abliva’s Chief Medical Officer Magnus Hansson to learn more about the company’s work in close cooperation with patient organisations.Read the article at biostock.se: https://www.biostock.se/en/2023/09/abliva-increases-awareness-of-mitochondrial-diseases/ This is a press release

    BioStock: Abliva receives FDA Fast Track designation

    Swedish biotech Abliva recently received FDA Fast Track designation for KL1333 – the company’s lead drug candidate for mitochondrial disease. KL1333 is currently being evaluated in the potentially registrational phase II study FALCON. BioStock reached out to CEO Ellen K. Donnelly for a comment.Read the full interview with Ellen K. Donnelly at biostock.se: https://www.biostock.se/en/2023/09/abliva-receives-fda-fast-track-designation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: First patient dosed in Abliva’s Falcon study

    In December Abliva started its phase II study to evaluate KL1333 in patients with primary mitochondrial disease. Earlier this week the company announced that the first patient in the study has been dosed. BioStock contacted Abliva CEO Ellen K. Donnelly to ask what this milestone means for the company.Read the article at biostock.se: https://www.biostock.se/en/2023/06/first-patient-dosed-in-ablivas-falcon-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    BioStock: First patient dosed in Abliva’s Falcon study

    In December Abliva started its phase II study to evaluate KL1333 in patients with primary mitochondrial disease. Earlier this week the company announced that the first patient in the study has been dosed. BioStock contacted Abliva CEO Ellen K. Donnelly to ask what this milestone means for the company.Read the full article at biostock.se : https://www.biostock.se/en/2023/06/first-patient-dosed-in-ablivas-falcon-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Abliva’s presence is felt at Euromit

    Held every three years, the Euromit meeting is happening this week in Bologna, Italy. Abliva, having now initiated their phase II FALCON study  in patients with primary mitochondrial disease, is attending the meeting this week.  The team will be presenting their research findings and engaging with experts in the field, further showcasing their commitment to advancing mitochondrial research and bringing innovative therapies to patients. BioStock contacted Abliva’s Chief Medical Officer, Magnus Hansson, to learn more.Read the article at biostock.se: https://www.biostock.se/en/2023/06/

    BioStock: FDA grants Abliva’s NV354 Orphan Drug Designation

    Biotech Abliva kicked the week off by announcing positive news from the United States. The FDA grants Abliva’s candidate NV354 Orphan Drug Designation, a designation that entails several regulatory advantages for the candidate. BioStock talked to CEO Ellen K. Donnelly about what this means for the development of NV354.Read the interview with Abliva's CEO Ellen K. Donnelly at biostock.se: https://www.biostock.se/en/2023/04/fda-grants-ablivas-nv354-orphan-drug-designation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    BioStock: Abliva’s CEO about the phase II study

    In December last year, Abliva initiated a potentially pivotal phase II study with KL1333. The candidate is being developed for the treatment of primary mitochondrial disease in adults, a group of rare diseases that lack effective treatment. CEO Ellen K. Donnelly visited BioStock’s studio to tell us more.See the full interview at biostock.se : https://www.biostock.se/en/2023/03/ablivas-ceo-about-the-phase-ii-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Abliva recruits Vice President of Clinical Operations

    Lund-based Abliva kicks off 2023 with a recruitment to strengthen the team. The biotech has appointed Dag Nesse to the position of Vice President, Clinical Operations. One of Nesse’s main task will be to oversee the operational aspects of the FALCON study with lead candidate KL1333. BioStock contacted Nesse to learn more about him and his new role.Read the full article at biostock.se: https://www.biostock.se/en/2023/02/abliva-recruits-vice-president-of-clinical-operations/ This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Abliva starts late-stage study with KL1333

    Lund-based biotech Abliva’s main goal for 2022 was to initiate clinical phase II studies with lead drug candidate KL1333. The company hit their target last week with the initiation of the FALCON study, a study designed with the potential to support registration of the drug for commercialisation. BioStock interviewed Abliva CEO Ellen Donnelly to learn more about this important study.Read the article at biostock.se: https://www.biostock.se/en/2022/12/abliva-starts-late-stage-study-with-kl1333/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.

    BioStock: Patient perspective in focus in Abliva’s phase II/III study

    Biotech company Abliva is now preparing for the perhaps biggest step in the company's history to date – a pivotal phase II/III study with the main candidate KL1333. When designing the study, the company has worked together with several patient organisations to gain a deeper understanding of the patients’ reality.Read the article at biostock.se: https://www.biostock.se/en/2022/11/patient-perspective-in-focus-in-ablivas-phase-ii-iii-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe